BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival

By /

Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug.

Scroll to Top